Guidance issued by NICE (England) for treating neuroendocrine tumours (NETs) Final guidance recommending everolimus (Infinitor, Novartis) and sunitinib (Sutent, Pfizer) to treat neuroendocrine tumours (NETs). The drugs are recommended as an option for pancreatic NETs that cannot be operated on and have progressed. Everolimus is also recommended as an option for those with NETs of…
Our Projects
